683 Capital Management LLC Raises Holdings in TG Therapeutics, Inc. $TGTX

683 Capital Management LLC boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 360,000 shares of the biopharmaceutical company’s stock after purchasing an additional 35,000 shares during the quarter. 683 Capital Management LLC’s holdings in TG Therapeutics were worth $10,732,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Danske Bank A S purchased a new stake in TG Therapeutics during the 3rd quarter worth about $25,000. Optiver Holding B.V. increased its holdings in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the period. Hantz Financial Services Inc. increased its holdings in TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the period. EverSource Wealth Advisors LLC increased its holdings in TG Therapeutics by 86.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 573 shares during the period. Finally, Truvestments Capital LLC increased its holdings in TG Therapeutics by 172.4% during the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

TGTX has been the topic of a number of recent analyst reports. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of TG Therapeutics in a report on Wednesday, May 27th. Finally, Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Stock Up 1.9%

Shares of NASDAQ TGTX opened at $51.50 on Thursday. The stock has a market cap of $7.88 billion, a PE ratio of 18.01 and a beta of 1.68. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $53.98. The business has a 50-day moving average price of $39.41 and a 200 day moving average price of $33.49.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The firm had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm’s revenue for the quarter was up 69.5% compared to the same quarter last year. During the same period last year, the company earned $0.03 earnings per share. Equities research analysts forecast that TG Therapeutics, Inc. will post 1.51 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.